The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Item
http://www.wikidata.org/entity/Q26768527
Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke.Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury.Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.Neuroendocrine abnormalities in Parkinson's disease.Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.Plant Polyphenols and Exendin-4 Prevent Hyperactivity and TNF-α Release in LPS-Treated In vitro Neuron/Astrocyte/Microglial Networks.The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders.Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells.Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review.Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation.The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's diseaseNeuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy
P2860

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Item
http://www.wikidata.org/entity/Q26768527
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@ast
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@en
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@nl
type
label
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@ast
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@en
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@nl
prefLabel
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@ast
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@en
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
The glucagon-like peptide 1 (G ...... disease: mechanisms of action
@en
P2093
P304
P31
P356
10.1016/J.DRUDIS.2016.01.013
P407
P433
P478
P50
P577
P698
P921